Pathologic fusion of the Ewing gene EWS to WT1 (t(11;22)(p13;q12)( EWS/WT1 )) has been shown to abrogate the tumour suppressor function of WT1 and to generate an oncogenic chimeric protein capable of binding and activating the IGF-1R promoter (Karnieli et al, 1996)
DOI: 10.3346/jkms.2014.29.6.811
Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, et al
And while we shouldnt reject a therapy just because its potent, we also shouldnt race ahead without asking: potent enough for whatand for how long
Therefore, they are nowadays recommended as first line therapy in patients with T2DM and atherosclerotic cardiovascular disease to reduce events, regardless of baseline or target HbA1c and concomitant glucose-lowering medication according to the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes [31]
after workouts) is not strongly supported by scientific evidence as a critical factor